Εσθονία - Εσθονικά - Ravimiamet

elanco animal health gmbh - permetriin+imidaklopriid - täpilahus - 3000mg+600mg 6ml 6ml 1tk; 3000mg+600mg 6ml 6ml 3tk; 3000mg+600mg 6ml 6ml 4tk; 3000mg+600mg 6ml 6ml 6tk

Εσθονία - Εσθονικά - Ravimiamet

elanco animal health gmbh - permetriin+imidaklopriid - täpilahus - 200mg+40mg 0.4ml 0.4ml 1tk; 200mg+40mg 0.4ml 0.4ml 6tk

Εσθονία - Εσθονικά - Ravimiamet

elanco animal health gmbh - permetriin+imidaklopriid - täpilahus - 2000mg+400mg 4ml 4ml 6tk; 2000mg+400mg 4ml 4ml 4tk; 2000mg+400mg 4ml 4ml 2tk

Εσθονία - Εσθονικά - Ravimiamet

elanco animal health gmbh - permetriin+imidaklopriid - täpilahus - 500mg+100mg 1ml 1ml 3tk; 500mg+100mg 1ml 1ml 2tk; 500mg+100mg 1ml 1ml 4tk; 500mg+100mg 1ml 1ml 1tk; 500mg+100mg 1ml 1ml 6tk

Εσθονία - Εσθονικά - Ravimiamet

elanco animal health gmbh - permetriin+imidaklopriid - täpilahus - 1250mg+250mg 2.5ml 2.5ml 2tk; 1250mg+250mg 2.5ml 2.5ml 3tk; 1250mg+250mg 2.5ml 2.5ml 4tk; 1250mg+250mg 2.5ml 2.5ml 6tk

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mitu müeloomit - antineoplastilised ained - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

intervet international b.v. - live myxoma vectored rhd viiruse tüve, 009, live myxoma vectored rhd viiruse tüve mk1899 - immunoloogilised ravimid jaoks jäneslased - küülikud - aktiivse immuniseerimise küülikud alates 5. elunädalast aastast vähendada suremust ja kliinilisi tunnuseid müksomatoosi ja küülikute hemorraagiline haigus (rhd), mis on põhjustatud klassikalise rhd viirus (rhdv1) ja rhd virus tüüp 2 (rhdv2).

Εσθονία - Εσθονικά - Ravimiamet

gp-pharm s.a. - oktreotiid - süstelahus - 100mcg 1ml 1ml 5tk

Εσθονία - Εσθονικά - Ravimiamet

gp-pharm s.a. - oktreotiid - süstelahus - 50mcg 1ml 1ml 5tk